• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.
Members

Institution

The Ottawa Hospital (General Campus)

City

Ottawa

Contact This Member

Shirley Mei

Dr. Shirley Mei is an Investigator at the Ottawa Hospital Research Institute.

Dr. Shirley Mei is an Investigator at the Ottawa Hospital Research Institute, who has a keen interest in translational medical research, specifically in the development of stem/progenitor cell and cell-based gene therapy strategies for sepsis/septic shock, acute lung injury and pulmonary arterial hypertension. She received her MSc from the Department of Biochemistry & Biomedical Sciences at McMaster University, and PhD from the Institute of Medical Science at the University of Toronto. Her research has shown that the administration of mesenchymal stem cells (MSCs) can reduce inflammation, vascular injury, and improve survival in animal models of acute lung injury and sepsis, supporting the potential benefits of using MSC-based cell therapy in humans. With a focus on bringing discoveries from the bench to the bedside, her current research includes essential preclinical work such as the development of GMP-compliant MSC products, the optimization of product safety and potency, the testing of cell products in relevant preclinical models, and the generation of toxicology data for regulatory submission. Working closely with a clinical team led by Dr. Lauralyn McIntyre and the world’s leader in cell therapeutics, Dr. Duncan Stewart, they initiated the Phase I Cellular Immunotherapy for Septic Shock (CISS) trial in April 2015, the first-in-human clinical trial to examine the safety and tolerability of MSCs for the treatment of septic shock. The Phase I trial was successfully completed in June 2016, with plans to start a larger Phase II multi-centre efficacy trial in 2018.